Anavex Life Sciences Corp (AVXL)

[Investor2014]

Depends a lot on what data and other announcements we may be presented with 1st week of November.

Let's say the PK/PD data is accompanied with longitudinal data, even for a sub group of the n=25, that continues to halt progression of Alzheimer's or better along with the P2/3 trial start announcement. If so the stock will rocket probably to around the $15 analyst target.

If the data continues to look encouraging, but for whatever reason perceived as inconclusive, then assuming trial design and start announcement based on the Ariana analysis, a guess between $5 - $6 sounds about right.